|
Pharma trade bodies have warned of negative impacts from tariffs, while analysts point to geopolitical catalysts.
|
 |
|
In 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers, despite US import tariffs on pharmaceuticals.
|
|
|
Under the agreement, Vertex will make a $15m upfront payment to Halozyme and potential future milestone payments.
|
|
|
RoosterBio’s CliniControl portfolio includes cGMP MSC expansion media, exosome collection media, and bioreactor feeds.
|
|
|
Apnimed will initially receive $50m at the deal’s closing.
|
|
|
The acquisition allows Neurocrine to offer three therapies: Ingrezza, Crenessity, and Vykat XR.
|
|
